Allowing for the limitations of small numbers, this study shows that the risk of inhibitor recurrence was about 4% in people with severe hemophilia A who had a normal FVIII half-life and 9.5% in those with evidence of low-level inhibitor activity and a reduced FVIII half-life. The gene discussed is F8; the disease is hemophilia A.